Vertex Pharma VRTX

HealthcareMarket cap $120B4 connections

Vertex Pharmaceuticals has a near-monopoly on cystic fibrosis treatment - its Trikafta (elexacaftor/tezacaftor/ivacaftor) is the first drug to treat the underlying cause of CF rather than symptoms, and is used by 90%+ of eligible patients globally. Its $4.9B CF drug revenues fund an R&D pipeline spanning pain (suzetrigine), kidney disease, and gene editing (with CRISPR Therapeutics).

Explore Vertex Pharma on the interactive map Relationship timeline Find a path to another company

Suppliers 1

Companies that sell to Vertex Pharma

IlluminaHealthcare · $20BGenomic sequencing for CF research

Partners 1

Strategic partnerships, joint products and alliances

CRISPR TherapeuticsHealthcare · $4BCRISPR Therapeutics co-developer with Vertex

Competitors 2

Companies it competes with

AmgenHealthcare · $160BRare disease market
RegeneronHealthcare · $100BRare disease drug competition

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Vertex Pharma's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=VRTX" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Vertex Pharma on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.